RxDoctor Payments Data

Rafael Mendoza Rodriguez

General Practice · Ponce, PRNPI 1780728873

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $57,650 of the $77,013 with a category attached, or 74.9%. Johnson & Johnson accounts for 61.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $34,298 and has fallen 91.3% since, to $2,973 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$77,013in general payments, 2019–2025

Across 191 payments — averaging $403.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$47K
  • Janssen Scientific Affairs, LLC$10K
  • Merck$8K
  • Viiv Healthcare Company$5K
  • Gilead$4K
  • Janssen Products, LP$3K
  • plus $344 from 5 others
$514,557in research payments, 2019–2025

Across 116 payments — averaging $4435.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$351K
  • AbbVie$163K

What the payments were for

  • Consulting fees$8,54011%
  • Speaking & faculty fees$57,65075%
  • Travel & lodging$6,8999%
  • Food & beverage$3,6315%
  • Education$2930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,013 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala135$551,103
TriumeqAbacavir/Dolutegravir/Lamivudi43$181,592
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf37$174,835
DovatoDolutegravir Sodium/Lamivudine36$130,913
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$105,274
Egrifta SvTesamorelin Acetate11$94,840
DescovyEmtricitabine/Tenofov Alafenam40$87,270
JulucaDolutegravir/Rilpivirine20$77,662
Isentress HdRaltegravir Potassium28$55,283
TivicayDolutegravir Sodium15$33,581
EliquisApixaban22$11,907
SynthroidLevothyroxine Sodium26$1,707
HumalogInsulin Lispro15$1,427
Divalproex Sodium16$1,220
Sulindac27$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,919$638,374175 claims
Viiv Healthcare CompanyTriumeq, Dovato, Juluca, Tivicay$4,619$423,749114 claims
Janssen Products, LPSymtuza$2,928$174,83537 claims
Theratechnologies Inc.Egrifta Sv$134$94,84011 claims
MerckIsentress Hd$7,690$55,28328 claims
AbbVieSynthroid$134$1,70726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →